| Objective To explore the relationship between serum chemerin level and bone mineral density (BMD) in type 2 diabetic patients. Methods The inpatients with type 2 diabetes were chosen from January 2012 to December 2014 in the Department of Endocrinology of our Hospital. BMD were measured with dual energy X-ray absorptiometry. Patients were divided into type 2 diabetic normal bone mass group (n= 42) , type 2 diabetic osteopenia group (n = 50), and type 2 diabetic osteoporosis group (n = 58)，according to the WHO diagnostic criteria of osteoporosis. Height, weight, duration of diabetes, and other clinical data were recorded. Fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c) , serum chemerin, TNF-α, and interleukin- 6 (IL-6) were measured. Another 30 cases of normal people were also included in the study as the control group. Results No significant difference of age and sex, height, weight, duration of diabetes，and HbA1c was found in the type 2 diabetic patients among the three groups. Serum chemerin level in type 2 diabetic osteoporosis group was significantly higher than that in type 2 diabetic osteopenia and normal bone mass group (89. 7 ± 12. 2μg /L，72. 5 ± 13. 6，and 65. 1 ± 14.9μg /L，P<0. 05). The TNF-α and IL-6 levels in diabetic osteoporosis group were significantly higher than those in type 2 diabetic normal bone mass group (P < 0. 05). Correlation analysis showed that；serum chemerin level was positively correlated with TNF-α, BMI, HbA1c, and duration of diabetes (r1 =0. 52, r2 = 0. 76, r3 = 0. 63, r4 =0. 59, P <0. 05), but was negatively correlated with BMD of LI-4 (r = -0.67, P < 0. 05 ). Conclusion Chemerin may be involved in the pathogenesis of diabetic osteoporosis by regulating inflammatory reaction, therefore promotes the occurrence of osteoporosis. |